​

Wave Life Sciences (WVE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WVE Stock Forecast

Wave Life Sciences (WVE) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $18.67, with a high of $26.00 and a low of $12.00. This represents a 145.01% increase from the last price of $7.62.

- $6 $12 $18 $24 $30 High: $26 Avg: $18.67 Low: $12 Last Closed Price: $7.62

WVE Stock Rating

Wave Life Sciences stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 1 Strong Buy (5.26%), 16 Buy (84.21%), 2 Hold (10.53%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 2 16 1 Strong Sell Sell Hold Buy Strong Buy

WVE Price Target Upside V Benchmarks

TypeNameUpside
StockWave Life Sciences145.01%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts134
Avg Price Target$12.00$18.67$23.00
Last Closing Price$7.62$7.62$7.62
Upside/Downside57.48%145.01%201.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 252121--15
Sep, 252121--15
Aug, 253111--15
Jul, 25391--13
Jun, 252101--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Steve SeedhouseCantor Fitzgerald$12.00$7.1368.30%57.48%
Sep 04, 2025Tiago FauthWells Fargo$18.00$8.00125.00%136.22%
Nov 12, 2024Joon LeenTruist Financial$36.00$13.49166.86%372.44%
Oct 21, 2024Luca IssiRBC Capital$15.00$14.801.35%96.85%
Oct 17, 2024Tiago FauthWells Fargo$22.00$14.9047.65%188.71%
Oct 16, 2024Strong BuyRaymond James$22.00$14.8148.55%188.71%
Oct 16, 2024Joseph SchwartzLeerink Partners$22.00$15.0546.18%188.71%
Oct 03, 2024Madison El-SaadiB.Riley Financial$19.00$8.65119.65%149.34%
Sep 25, 2024Salim SyedMizuho Securities$19.00$8.19131.99%149.34%
Sep 25, 2024Madison El-SaadiB.Riley Financial$11.00$8.1934.31%44.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2025Cantor FitzgeraldOverweightOverweighthold
Sep 04, 2025B. RileyBuyBuyhold
Sep 04, 2025Wells FargoOverweightOverweighthold
Jul 28, 2025OppenheimerOutperforminitialise
Jul 16, 2025CitigroupBuyinitialise
Oct 21, 2024RBC CapitalSector PerformSector Performhold
Oct 17, 2024H.C. WainwrightBuyBuyhold
Oct 17, 2024Wells FargoOverweightOverweighthold
Oct 16, 2024Raymond JamesOutperformStrong Buyupgrade
Oct 03, 2024B. RileyBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.82$-2.36$-2.05$-0.54$-0.70----
Avg Forecast$-3.75$-2.22$-2.01$-0.62$-1.19$-0.98$-0.75$-0.21$0.45
High Forecast$-0.90$-0.53$-0.29$-0.38$-0.90$-0.69$0.10$0.70$0.70
Low Forecast$-6.44$-3.82$-3.37$-0.88$-1.43$-1.51$-1.14$-0.89$0.03
Surprise %1.87%6.31%1.99%-12.90%-41.18%----

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$20.08M$40.96M$3.65M$113.31M$108.30M----
Avg Forecast$20.48M$52.67M$9.40M$103.99M$53.01M$76.29M$113.19M$219.35M$373.63M
High Forecast$31.78M$81.72M$14.29M$126.87M$96.87M$100.96M$114.35M$313.42M$533.87M
Low Forecast$8.51M$21.88M$3.22M$81.71M$26.89M$34.95M$112.03M$61.39M$104.57M
Surprise %-1.98%-22.23%-61.19%8.95%104.30%----

Net Income Forecast

$-700M $-540M $-380M $-220M $-60M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-149.91M$-122.25M$-161.82M$-57.51M$-97.01M----
Avg Forecast$-398.13M$-235.84M$-213.43M$-57.51M$-142.52M$-151.58M$-55.12M$-42.89M$47.74M
High Forecast$-95.58M$-56.62M$-31.09M$-40.72M$-94.98M$-72.89M$10.30M$74.61M$74.36M
Low Forecast$-683.50M$-404.88M$-357.77M$-93.88M$-151.31M$-160.55M$-120.55M$-94.03M$3.05M
Surprise %-62.35%-48.17%-24.18%--31.93%----

WVE Forecast FAQ

Is Wave Life Sciences stock a buy?

Wave Life Sciences stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 16 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Wave Life Sciences is a favorable investment for most analysts.

What is Wave Life Sciences's price target?

Wave Life Sciences's price target, set by 19 Wall Street analysts, averages $18.67 over the next 12 months. The price target range spans from $12 at the low end to $26 at the high end, suggesting a potential 145.01% change from the previous closing price of $7.62.

How does Wave Life Sciences stock forecast compare to its benchmarks?

Wave Life Sciences's stock forecast shows a 145.01% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Wave Life Sciences over the past three months?

  • October 2025: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 13.33% Strong Buy, 80.00% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 20.00% Strong Buy, 73.33% Buy, 6.67% Hold, 0% Sell, 0% Strong Sell.

What is Wave Life Sciences’s EPS forecast?

Wave Life Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.98, marking a 40.00% increase from the reported $-0.7 in 2024. Estimates for the following years are $-0.75 in 2026, $-0.21 in 2027, and $0.45 in 2028.

What is Wave Life Sciences’s revenue forecast?

Wave Life Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $76.29M, reflecting a -29.56% decrease from the reported $108.3M in 2024. The forecast for 2026 is $113.19M, followed by $219.35M for 2027, and $373.63M for 2028.

What is Wave Life Sciences’s net income forecast?

Wave Life Sciences's net income forecast for the fiscal year ending in December 2025 stands at $-152M, representing an 56.26% increase from the reported $-97.008M in 2024. Projections indicate $-55.124M in 2026, $-42.886M in 2027, and $47.74M in 2028.